FGF21 and myeloid sarcoma: It has been reported that the CSF level of FGF21 is approximately 40% of its level in circulation in healthy subjects (Tan et al. 2011) due to limited entry of FGF21 into the CNS through the BBB, suggesting that peripheral administration of FGF21 may not effectively effective in the management of MS.